Aziyo appoints Dr. C. Randal Mills Interim CEO, Ronald Lloyd steps down; reaffirms FY22 guidance $47-50M

ELUTIA INC.

CEO Ronald Lloyd steps down effective June 21; co-founder C. Randal Mills appointed Interim President and CEO.
Mills receives $600k base salary, 60% target bonus, option to purchase 456,278 shares, and 224,734 RSUs with time/performance vesting.
Lloyd remains employee through Sep 30 for transition; eligible for 12-month cash severance plus up to $1M performance bonus.
Mills' move from Audit Committee leaves it with two independent members; Nasdaq cure period of 180 days.
Company reaffirms FY2022 net sales guidance of $47–$50 million.

item 3.01 item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Ronald Lloyd

President and Chief Executive Officer

ELUT · ELUTIA INC.

Effective: 2022-06-21
Successor: C. Randal Mills
Filed: June 21, 2022, 7:59 PM ET

Ronald Lloyd, who will be stepping down as the Company’s President and Chief Executive Officer and as a member of the Board, in each case, effective June 21, 2022

Appointed (interim)

C. Randal Mills

Interim President and Chief Executive Officer

ELUT · ELUTIA INC.

Effective: 2022-06-21
Filed: June 21, 2022, 7:59 PM ET

On June 20, 2022, C. Randal Mills, Ph.D., a member of the Board of Directors (the “Board”) of Aziyo Biologics, Inc. (the “Company”), was appointed as the Company’s Interim President and Chief Executive Officer

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Ronald Lloyd departed as President and Chief Executive Officer at ELUTIA INC..

Action: stepped down
Role: President and Chief Executive Officer

Exact text from the filing

Ronald Lloyd, who will be stepping down as the Company’s President and Chief Executive Officer and as a member of the Board, in each case, effective June 21, 2022

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

C. Randal Mills was appointed as Interim President and Chief Executive Officer at ELUTIA INC..

Action: appointed
Role: Interim President and Chief Executive Officer

Exact text from the filing

On June 20, 2022, C. Randal Mills, Ph.D., a member of the Board of Directors (the “Board”) of Aziyo Biologics, Inc. (the “Company”), was appointed as the Company’s Interim President and Chief Executive Officer

View on SEC.gov

ELUTIA INC. filing history →

Source: SEC EDGAR

accession 0001104659-22-072962

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.